Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Primary Systemic Amyloidosis Clear all
Terminated No phase listed Observational
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fentanyl citrate, pharmacological study
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced May 21, 2026, 7:24 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, recombinant interferon alfa
Biological
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1999
U.S. locations
5
States / cities
Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced May 21, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Primary Systemic Amyloidosis
Interventions
bortezomib, cyclophosphamide, dexamethasone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced May 21, 2026, 7:24 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Interventions
JNJ-79635322
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
9
States / cities
Duarte, California • Irvine, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 7:24 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Amyloidosis
Interventions
blood collection, bone marrow collection
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced May 21, 2026, 7:24 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
AL Amyloidosis, Amyloidosis
Interventions
non-interventional
Other
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced May 21, 2026, 7:24 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, Magnetic Resonance Imaging, Melphalan, Positron Emission Tomography, Stem Cell Isolation, Survey Administration
Procedure · Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
117
States / cities
Goodyear, Arizona • Tucson, Arizona • Duarte, California + 93 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 21, 2026, 7:24 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
educational intervention
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Detroit, Michigan • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced May 21, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Bendamustine, Dexamethasone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced May 21, 2026, 7:24 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Immunoglobulin Light Chain (AL) Amyloidosis
Interventions
ABBV-383 (Etentamig)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
12
States / cities
Miami, Florida • Boston, Massachusetts • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 7:24 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
educational intervention, Titrated pain management, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
11
States / cities
Hopkinsville, Kentucky • Owensboro, Kentucky • Chattanooga, Tennessee + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced May 21, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
darbepoetin alfa, epoetin alfa, fatigue assessment and management, quality-of-life assessment
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced May 21, 2026, 7:24 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Amyloidosis, Transthyretin Amyloidosis
Interventions
124I-Evuzamitide
Diagnostic Test
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 21, 2026, 7:24 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Amyloidosis, Amyloid, Amyloid Neuropathies, Familial, Amyloid Cardiomyopathy, Amyloid - Primary, Transthyretin Amyloidosis, AL Amyloidosis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced May 21, 2026, 7:24 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Primary Amyloidosis
Interventions
124I-labeled monoclonal antibody Mu 11-1F4
Biological
Lead sponsor
University of Tennessee
Other
Eligibility
21 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced May 21, 2026, 7:24 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Venetoclax, Dexamethasone
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced May 21, 2026, 7:24 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
4'-iodo-4'-deoxydoxorubicin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
2
States / cities
Little Rock, Arkansas • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 11, 2012 · Synced May 21, 2026, 7:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions
therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced May 21, 2026, 7:24 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Light Chain Deposition Disease, Primary Systemic Amyloidosis
Interventions
melphalan, dexamethasone, bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
209
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Aurora, Colorado + 140 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced May 21, 2026, 7:24 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epoetin alfa
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced May 21, 2026, 7:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
Human immune globulin intravenous (IGIV)
Biological
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Knoxville, Tennessee • Powell, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced May 21, 2026, 7:24 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Amyloidosis
Interventions
Melphalan, Autologous Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2008 · Synced May 21, 2026, 7:24 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, recombinant interferon alfa, sargramostim, busulfan, cyclophosphamide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced May 21, 2026, 7:24 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions
anti-thymocyte globulin, filgrastim, cladribine, cyclophosphamide, etoposide, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Up to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2012 · Synced May 21, 2026, 7:24 PM EDT